This study combines radiographic images and pathological microscopy with machine learning to generate predictive maps of pathological features (i.e. new contrasts) based on segmented histological features. Predictive cytological topography (PiCT) maps of cellularity were utilized to detect additional pathologically confirmed high-grade prostate cancer tumors missed by radiologists.
Figure 2 shows an example of the PiCT maps of lumen and cellular density compared to the actual features segmented from histology. Of the lesions identified on pathology, 26 were G4 fused glands (G4f), 13 were G4 cribriform glands (G4c), and six were G5. The PiCT maps detected an additional 11 G4f lesions and 3 G4c lesions missed by radiologists, while radiologists detected three G4f lesions and two G4c lesions missed by PiCT. Three G4f lesions and 2 G4c lesions were not detected by either radiologists or PiCT. Both PiCT and radiologists detected the same five G3 lesions and missed the same one G5 lesion. The ROC area under the curve (AUC) for PiCT maps was 0.896 and the AUC for PI-RADS was 0.753 (P<0.0001 for both) (Figure 3).
1. Nagarajan R, Margolis D, Raman S, et al. Correlation of Gleason scores with diffusion-weighted imaging findings of prostate cancer. Advances in urology. 2012;2012:374805.
2. Mazaheri Y, Hricak H, Fine SW, et al. Prostate tumor volume measurement with combined T2-weighted imaging and diffusion-weighted MR: correlation with pathologic tumor volume. Radiology. 2009;252(2):449-457.
3. Panebianco V, Barchetti F, Sciarra A, et al. Multiparametric magnetic resonance imaging vs. standard care in men being evaluated for prostate cancer: a randomized study. Urologic oncology. 2015;33(1):17 e11-17.
4. Vargas HA, Hotker AM, Goldman DA, et al. Updated prostate imaging reporting and data system (PIRADS v2) recommendations for the detection of clinically significant prostate cancer using multiparametric MRI: critical evaluation using whole-mount pathology as standard of reference. European radiology. 2016;26(6):1606-1612.
5. Weinreb JC, Barentsz JO, Choyke PL, et al. PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2. Eur Urol. 2016;69(1):16-40.
6. Panebianco V, Barchetti F, Barentsz J, et al. Pitfalls in Interpreting mp-MRI of the Prostate: A Pictorial Review with Pathologic Correlation. Insights into imaging. 2015.
7. Notley M, Yu J, Fulcher AS, Turner MA, Cockrell CH, Nguyen D. Diagnosis of recurrent prostate cancer and its mimics at multiparametric prostate MRI. Br J Radiol. 2015;88(1054):20150362.
8. Priester A, Natarajan S, Le JD, et al. A system for evaluating magnetic resonance imaging of prostate cancer using patient-specific 3D printed molds. American journal of clinical and experimental urology. 2014;2(2):127-135.
9. Turkbey B, Mani H, Shah V, et al. Multiparametric 3T prostate magnetic resonance imaging to detect cancer: histopathological correlation using prostatectomy specimens processed in customized magnetic resonance imaging based molds. The Journal of urology. 2011;186(5):1818-1824.
10. Nguyen HS, Milbach N, Hurrell SL, et al. Progressing Bevacizumab-Induced Diffusion Restriction Is Associated with Coagulative Necrosis Surrounded by Viable Tumor and Decreased Overall Survival in Patients with Recurrent Glioblastoma. AJNR Am J Neuroradiol. 2016.